Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS3692493 A
Publication typeGrant
Publication dateSep 19, 1972
Filing dateSep 22, 1970
Priority dateSep 22, 1970
Publication numberUS 3692493 A, US 3692493A, US-A-3692493, US3692493 A, US3692493A
InventorsPaul I Terasaki
Original AssigneeUs Health Education & Welfare
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Lymphocyte transport bag
US 3692493 A
Abstract  available in
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

p 19, 1972 P. l. TERASAKI LYMPHOGYTE TRANSPORT BAG Filed Sept. 22 1970 FIG. i

INVENTOR PAUL l. TERASAKI ATTORNEYS United States Patent *Ofice 3,692,493 Patented Sept. 19, 1972 3,692,493 LYMPHOCYTE TRANSPORT BAG Paul I. Terasaki, Los Angeles, Calif., assignor to the United States of America as represented by the Secretary, Department of Health, Education, and Welfare Filed Sept. 22, 1970, Ser. No. 74,276 Int. Cl. B011 3/00 U.S. Cl. 23-259 6 Claims ABSTRACT OF THE DISCLOSURE A compartmented mixing and shipping bag for blood. The bag, formed of plastic, is provided with three com partments; the first compartment, into which the blood is injected, contains nylon to which the undesirable gran nlocytes adhere. A second compartment contains a flushing ingredient and the seal between the first and second chambers is broken and the flushing medium is used to flush the lymphocytes from the first chamber into a third chamber. The third chamber is separated from the first two chambers and is used as a shipping container.

The present invention relates to a separating and shipping system and, more particularly, to the shipment of human blood lymphocytes for extended distances and without degradation.

Blood typing is an extremely important consideration in the transplantation of human organs in order to match donors and recipients for kidney, heart and other organs. The lymphocyte cytotoxicity method appears to be the most widely used for determination of human histocompatibility antigens. One of the advantages of the lymphocyte cytotoxicity test over the leukoagglutination test is the fact that lumphocytes can be kept in a testable condiion longer than granulocytes can. This is an important consideration since the typing work is complex and the need exists to send samples to the limited number of qualified labs; lymphocytes will die within two days if blood is sent by currently available means. Accordingly, the need for better shipment methods is acute.

This need for the development of better means for transporting lymphocyte specimens is increased by recent evidence that HL-A antigens are important in man, with the attendant need to cross-check typing results in several typing laboratories. Collaborative efforts made possible by exchanges of sera have resulted in extremely rapid advances in the past few years and a system permitting more frequent exchanges of cells among leukocyte-typing laboratories can be expected to result in further advances.

It is, accordingly, an object of the present invention to provide for the improved shipping of unstable materials.

It is another object of the present invention to provide for the improved transportation of lumphocyte specimens.

It is another object of the present invention to provide an improved container for shipping lymphocyte specimens.

It is another object of the present invention to provide a simplified and inexpensive device and method for separating an undesirable or desirable blood component, retaining the desirable component and shipping the desirable component safely to a distant location.

These and other objects and the nature and advantages of the instant invention will be more apparent from the following detailed description of an embodiment, taken in conjunction with the drawing wherein:

FIG. 1 is a sectional view of an embodiment of a device in accordance with the present invention, showing one stage of its use;

FIG. 2 is a sectional View showing the device of FIG. 1 in a second stage of its use; and

FIG. 3 is a plan view of the device of FIGS. 1 and 2 shown in its third stage of its use.

A preferred embodiment of the present invention is illustrated in FIGS. 1-3 which shows a plastic bag divided into three sections or compartments. The basic principle of the bag is to remove the granulocytes from the blood in the first section of the bag, for it is the early death and subsequent release of enzymes from these dead cells which causes the death of lymphocytes. Thus, the bag 10, preferably formed of polyvinyl chloride, although it may be formed of any suitable plastic, is provided with a first compartment 12, a second compartment 14, and a third compartment 16. A blood inlet 18 is provided for the first compartment 12, and a frangible separating wall 20 is provided between the first and second compartments 12 and 14. A perforated separating wall 22 separates the third compartment 16 from the first and second compartments 12 and 14, and the interior of the first compartment 12 is connected to the interior of the third compartment 16 by means of a tube 24.

Very briefly, in usage, blood is injected into chamber 12, which contains a granulocyte adhering material such as nylon, through the port 18. After coating the nylon with blood, the seal 20 between the first chamber 12 and the second chamber 14 is broken, allowing the media in compartment 14 to flush the lymphocytes from the nylon in compartment 12 as illustrated in FIG. 2. Since granulocytes will be adherent to the nylon, they will not be flushed out into the third compartment 16 as will the lymphocytes. The third chamber 16, preferably containing an absorbent material such as cotton, serves to retain the lymphocytes, red cells and the media. The chamber 16 is separated along the perforation 22, the tubing 24 is cut close to chamber 12 and is then tied. The compartment 16 may then be mailed to any suitable lab with an attached label.

The flushing medium initially present in the second compartment 14 and in which the lymphocytes are transported ultimately in the third compartment 16 should be a tissue culture medium. One known tissue culture medium which has been tested and is highly effective is McCoys medium; this medium includes L-glutamine, antibiotics and 30% fetal calf serum, and is known to be effective for pro agating leukocytes, issues from biopsy specimens, and the most fastidious of primary and perpetually cultivated cell strains (McCoy, T. A. et al.; Proc. Soc. Exper. Biol. & Med., V. 100, pages -118, 1959). Other tissue culture media are also satisfactory, e.g. me-

dium 199 has been used successfully. A medium which is less complex than McCoys medium may be used if desired.

The form of the nylon in compartment 12 is not critical and in one example nylon tricot has been used successfully. In other words, the nylon may be in woven fabric form, in fibrous form, in granular form. Although any type of nylon may be used, nylon 66 which is readily available in cloth form is preferred. Any material may be substituted for nylon which will serve the function of causing adherance of the granulocytes.

With regard to the adsorbent material in the shipping compartment 16, any absorbent pad may be used. Tampons produced by Tampex of Palmer, Mass. have been sucessfully used. The absorbent material in shipping container 16 serves to minimize leakage in case a tear develops in the container wall during shipping, and serves a supplementary purpose in trapping any granulocytes which may not have been removed in the first compartment 12.

If desired, a two chamber bag may be used in place of the illustrated three chamber bag 10. In this event, a chamber corresponding to the second chamber 14 of the three compartment bag is eliminated and the tissue culture medium, used for flushing, is added from an outside source, such as through the same opening through which the blood has previously been injected.

In use (see Transplantation, vol. 8, No. 3, published Sept. 26, 1969, pgs. 311-314), milliliters of heparinized blood are injected into chamber 12 containing nylon tricot. The blood is kneaded well into the nylon and the granulocytes adhere to the fibers within 2-5 minutes. Then, ml. of McCoys medium without calf serum are added to flush out red cells and lymphocytes through the tube 24 and into the chamber 16. Chamber 12 must be squeezed tightly to transfer the blood-media mixture into chamber 16 containing an absorbent pad. Bag 16 is then torn along the perforated line and tube 24 is cut close to compartment 12; bag 16 is then tied and labeled and may, if desired, be sent through the mail by special delivery.

Upon receipt, the bag 16 is put in a 50-ml. syringe or a bag squeezing device, 10 ml. of saline are added and the bag is squeezed tightly with the plunger. The effluent is centrifuged, the bufiy coat is removed, and the red cells are agglutinated in accordance with known procedures (e.g. Terasaki et al., Ann. Rev. Med, vol. 20, page 175).

Blood was received by ordinary air mail special delivery from England, Switzerland, Japan, Venezuela, Israel, and Canada with 80-90% viable cells. In all instances, the samples were received within 3 /2 days of bleeding. The yield has been in the range of 180,000 cells-1,000,000 purified lymphocytes. Considerable variability in yield was encountered, for many patients were uremic or cadaver donors. A trend toward loss in yield and in viability with time occured. Blood from normal persons stored at room temperature for 7-8 days showed some loss in viability and yield but was suitable for typing. Over 180 tests could be set up readily by the microtest. At times, if the nylon had not been strongly squeezed by the sending center, it was possible to reflush the nylon chamber if more lymphocytes were needed. Debris presumably contributed by lysed granulocytes, as well as by intact granulocytes, was almost completely absent in these preparations.

Whether lymphocytes stored for 7 days could be typed by the cytotoxicity test was then investigated. Storage could alter the cell membrane so that the cell might be more susceptible to lysis, or it could produce an apparent loss in antigenicity by loss in combining sites on the surface. he lymphocytes of 11 persons were tested accordingly on the day after bleeding and after 7 days of storage with 54-108 cytotoxic antisera representing 12 HLA specificities are seen from the following table.

Effect of storage on HL-A typing lymphocytes Antiserum reactions v Discrep- Lymphocytes were isolated from blood on the day of collection and following 7 days of storage. The cells were tested on a panel of 54-108 antisera representing 12 HL-A specificities.

0 F, fresh cells; S, stored or 7 days.

Although some variations in reactions with different antisera were found, no changes in the HL-A classification of the cell were produced and no loss or gain of HL-A specificity occurred. With respect to each antiserum reaction, it can be noted that 84-100% of the reactions with each cell were reproducible after 7 days of storage, and the few discreptancies appeared to occur randomly.

It will be understood that various changes may be made without departing from the scope of the invention. For example, the flushing and storage fluid, i.e. the tissue culture medium, may vary in composition; further, changes may be made in the construction of the bag, i.e. for ease in mailing, another bag in which the nylon compartment can be separated from the second compartment may be provided, thus permitting the mailing of a simple small pad. Also, the selection of the material from which the bag is made variable.

The foregoing description of the specific embodiment will fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify such specific embodiment and/or adapt it for various applications without departing from the generic concept and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalence of the disclosed embodiments. It is to be understood that the phraseology and terminology employed herein is for the purpose of description and not of limitation.

What is claimed is:

1. A construction for the separation of blood components and the subsequent shipping of said components, said construction comprising:

means to receive and contain a blood sample, said means comprising a first compartment formed of flexible material, said compartment containing means to retain granulocytes from said blood sample, and said first compartment being further provided with means for the feeding thereto of a flushing tissue culture medium; and

a shipping container detachably connected to said first compartment and formed of a flexible material, and passageway means between said first compartment and said shipping container for the passage therethrough of lymphocytes from said blood sample and said tissue culture medium.

2. A construction in accordance with claim 1 wherein said shipping container is filled with an absorbent material.

3. A device in accordance with claim 2 wherein said granulocyte retaining material in said first compartment is nylon and wherein said absorbent material in said shipping container is cotton.

4. A device in accordance with claim 1 of initially unitary construction and wherein said flexible material is plastic film, said first compartment being joined to said shipping container by a perforated connection, and said passageway means comprising a tube running between said first compartment and said shipping container independant of said perforation connection.

5. A device in accordance with claim 4 further comprising as part of said unitary structure means to initially contain said tissue culture medium, and wherein said means to feed said tissue culture medium to said first compartment comprises a frangible separation between said first compartment and said means to contain said tissue culture medium.

6. A device in accordance with claim 5 wherein said tissue culture medium is McCoys medium.

References Cited UNITED STATES PATENTS 6 3,064,647 11/1962 Earl 23-2585 3,257,072 6/1966 Reynolds 20647 AX 3,304,977 2/ 1967 Hammons 128272 X 3,351,432 11/1967 Van Dyck et a1. 23258.5 3,399,040 8/1968 Ilg 23-2585 3,452,924 7/1969 Schlutz 23258.5 UX 3,480,398 11/1969 Hamilton 23253 R 3,545,671 12/1970 Ross 128214 DX 3,561,186 2/ 1971 Pickering 23-292 X 3,563,859 2/1971 Fink 195127 3,579,303 5/1971 Pickering 23292 X BARRY S. RICHMAN, Primary Examiner US. Cl. X.R.

23-230 B, 253 R, 258.5, 292; 128-272; l95-1.8, 127; 20 47 A

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3894845 *May 24, 1973Jul 15, 1975Bernard McdonaldUrine collection and analysis device
US4619650 *Apr 9, 1985Oct 28, 1986Miles Laboratories, Inc.Plasma bags
US5114004 *Feb 12, 1991May 19, 1992Material Engineering Technology Laboratory Inc.Filled and sealed, self-contained mixing container
US5353927 *Feb 24, 1993Oct 11, 1994Illinois Tool Works Inc.Plural compartment package
US5695989 *Aug 3, 1995Dec 9, 1997Cellpro, Inc.Apparatus and method for separating particles using a pliable vessel
US6027938 *Mar 20, 1998Feb 22, 2000Barnes; Allen C.Micropathological patient replica based on unadulterated whole blood
US6186998 *May 29, 1998Feb 13, 2001Hosokawa Yoko Co., Ltd.Bag for infusion solution and method of manufacturing same
US6364864Jun 3, 1999Apr 2, 2002Baxter International Inc.Plastic containers having inner pouches and methods for making such containers
US6565802Jun 3, 1999May 20, 2003Baxter International Inc.Apparatus, systems and methods for processing and treating a biological fluid with light
US6986867Jul 29, 2002Jan 17, 2006Baxter International Inc.Apparatus, systems and methods for processing and treating a biological fluid with light
US7025877Jun 3, 1999Apr 11, 2006Baxter International Inc.Processing set for processing and treating a biological fluid
US7068361Oct 11, 2002Jun 27, 2006Baxter InternationalApparatus, systems and methods for processing and treating a biological fluid with light
US7105093Oct 8, 2002Sep 12, 2006Baxter International Inc.Processing set and methods for processing and treating a biological fluid
US7175614Oct 17, 2002Feb 13, 2007Baxter International Inc.Peelable seal
US7425304Feb 13, 2006Sep 16, 2008Fenwal, Inc.Processing set and methods for processing and treating a biological fluid
US7445756Oct 11, 2002Nov 4, 2008Fenwal, Inc.Fluid processing sets and organizers for the same
US7459695Jul 27, 2005Dec 2, 2008Fenwal, Inc.Apparatus, and systems for processing and treating a biological fluid with light
US7546918Dec 19, 2006Jun 16, 2009Baxter International Inc.Peelable seal
US7601298May 31, 2006Oct 13, 2009Fenwal, Inc.Method for processing and treating a biological fluid with light
US7678097Nov 12, 1999Mar 16, 2010Baxter International Inc.Containers and methods for manufacturing same
US7770611Oct 26, 2006Aug 10, 2010Baxter International Inc.Peelable seal closure assembly
US7910361Aug 9, 2007Mar 22, 2011Barnes Allen CPortable biological testing device and method
US8518637Feb 22, 2011Aug 27, 2013Allen C. BarnesMethod of providing portable biological testing capabilities
US9004761May 1, 2006Apr 14, 2015Baxter International Inc.Multiple chamber container with mistake proof administration system
DE2819574A1 *May 5, 1978Nov 30, 1978Jan Ingemar NaeslundVerfahren und vorrichtung zur verarbeitung einer koerperfluessigkeitsprobe
WO1992007243A1 *Oct 18, 1991Apr 30, 1992Cellpro IncAn apparatus and method for separating particles using a pliable vessel
WO1994018891A1 *Feb 21, 1994Sep 1, 1994Trinity Res LtdApparatus for the collection and recovery of saliva for use in diagnostic assays
WO1994018892A1 *Feb 21, 1994Sep 1, 1994Trinity Res LtdDevice for the processing of saliva for use in an immunoassay
WO1998041609A1 *Mar 20, 1998Sep 24, 1998Allen C BarnesMicropathological patient replica based on unadulterated whole blood
U.S. Classification422/555, 435/2, 206/219, 604/410, 422/944, 436/63, 604/416
International ClassificationB01L3/00, G01N33/49
Cooperative ClassificationG01N33/491, B01L3/505
European ClassificationB01L3/505, G01N33/49C